A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
- Indications Glioma
- Focus Therapeutic Use
- Acronyms DIPG
- Sponsors Burzynski Research Institute
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Apr 2016 Status changed from planning to recruiting, as per Burzynski Research Institute media release.
- 30 Oct 2014 New trial record